Oculis
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.
Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.
Licaminlimab eye drops three times daily (TID) for 29 days.
Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.